Prevalence of resistance-associated mutations in newly diagnosed HIV-1 patients in Greece

Virus Research

Volumn 112, Issue 1-2, 2005, Pages 115-122

  Paraskevis, D ^a   Magiorkinis, E ^a   Katsoulidou, A ^a   Hatzitheodorou, E ^a   Antoniadou, A ^b   Papadopoulos, A ^b   Poulakou, G ^b   Paparizos, V ^c   Botsi, C ^c   Stavrianeas, N ^c   Lelekis, M ^d   Chini, M ^d   Gargalianos, P ^d   Magafas, N ^e   Lazanas, M ^e   Chryssos, G ^f   Petrikkos, G ^g   Panos, G ^h   Kordossis, T ^g   Theodoridou, M ⁱ   Sypsa, V ^a   Hatzakis, A ^a   Panagopoulos, P ^b   Tsogas, N ^e   Haratsis, G ^h   Kontos, A ^g   Mostrou, G ⁱ   more..

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c A Syngros Hospital   (Greece)

^d G GENNIMATAS GENERAL HOSPITAL   (Greece)

^e RED CROSS HOSPITAL   (Greece)

^f TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

^g Departments of Propedeutic Medicine   (Greece)

^h 1st IKA Hospital   (Greece)

ⁱ AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

Author keywords

Drug resistance; HIV 1; Na ve; Newly diagnosed; Subtypes

Indexed keywords

PROTEINASE; RNA DIRECTED DNA POLYMERASE;

ADULT; AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENE MUTATION; GREECE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; VIRUS RECOMBINANT; VIRUS TRANSMISSION; VIRUS TYPING;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GREECE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS; SEQUENCE ANALYSIS, DNA;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 22044433288     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2005.03.004     Document Type: Article

References (39)

1. M. Birk, and A. Sönnerborg Variations in the human immunodeficiency virus type 1 pol gene associated with reduced sensitivity to antiretroviral drugs in treatment naive patients AIDS 12 1998 2369 2375
2. D. Boden, A. Hurley, L. Zhang, Y. Cao, Y. Guo, E. Jones, J. Tsay, J. Ip, C. Farthing, K. Limoli, N. Parkin, and M. Markowitz HIV-1 drug resistance in newly infected individuals JAMA 282 1999 1135 1141
3. B.G. Brenner, J.P. Routy, M. Petrella, D. Moisi, M. Oliveira, M. Detorio, B. Spira, V. Essabag, B. Conway, R. Lalonde, R.P. Sekaly, and M.A. Wainberg Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection J. Virol. 76 2002 1753 1761
4. I. Derdelinckx, K. Van Laethem, B. Maes, Y. Schrooten, S. De Wit, E. Florence, K. Fransen, S.G. Ribas, D. Marissens, M. Moutschen, D. Vaira, G. Zissis, M. Van Ranst, E. Van Wijngaerden, and A.M. Vandamme Current levels of drug resistance among therapy-naive HIV-infected patients have significant impact on treatment response J Acquir. Immune Defic. Syndr. 37 2004 1664 1666
5. D. Descamps, V. Calvez, J. Izopet, C. Buffet-Janvresse, A. Schmuck, P. Colson, A. Ruffault, A. Maillard, B. Masquelier, J. Cottalorda, M. Harzic, F. Brun-Vezinet, D. Costagliola ANRS Antiretroviral Resistance Study Group Prevalence of resistance mutations in antiretroviral-naive chronically HIV-infected patients in 1998: a French nationwide study AIDS 15 2001 1777 1782
6. J. Durant, P. Clevenbergh, P. Halfon, P. Delgiudice, S. Porsin, P. Simonet, N. Montagne, C.A. Boucher, J.M. Schapiro, and P. Dellamonica Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial Lancet 353 1999 2195 2199
7. Z. Grossman, N. Vardinon, D. Chemtob, M.L. Alkan, Z. Bentwich, M. Burke, G. Gottesman, V. Istomin, I. Levi, S. Maayan, E. Shahar, J.M. Schapiro Israel Multi-Center Study Group Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B AIDS 15 2001 1453 1460
8. F.M. Hecht, R.M. Grant, C.J. Petropoulos, B. Dillon, M.A. Chesney, H. Tian, N.S. Hellmann, N.I. Bandrapalli, L. Digilio, B. Branson, and J.O. Kahn Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors N. Engl. J. Med. 339 1998 307 311
9. M.S. Hirsch, F. Brun-Vezinet, B. Clotet, B. Conway, D.R. Kuritzkes, R.T. D'Aquila, L.M. Demeter, S.M. Hammer, V.A. Johnson, C. Loveday, J.W. Mellors, D.M. Jacobsen, and D.D. Richman Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel Clin. Infect. Dis. 37 2003 113 128
10. J.P. Huelsenbeck, F. Ronquist, R. Nielsen, and J.P. Bollback Bayesian inference of phylogeny and its impact on evolutionary biology Science 294 2001 2310 2314
11. V.A. Johnson, F. Brun-Vezinet, B. Clotet, B. Conway, R.T. D'Aquila, L.M. Demeter, D.R. Kuritzkes, D. Pillay, J.M. Schapiro, A. Telenti, and D.D. Richman Update of the drug resistance mutations in HIV-1: 2004 Top HIV Med. 12 2004 119 124
12. L.B. Jorgensen, M.B. Christensen, J. Gerstoft, L.R. Mathiesen, N. Obel, C. Pedersen, H. Nielsen, and C. Nielsen Prevalence of drug resistance mutations and non-B subtypes in newly diagnosed HIV-1 patients in Denmark Scand. J. Infect. Dis. 35 2003 800 807
13. R. Kantor, and D. Katzenstein Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution AIDS Rev. 5 2003 25 35
14. C.L. Kuiken B. Foley E. Freed B. Hahn B. Korber P.A. Marx F. McCutchan J.W. Mellors S. Wolinksy HIV Sequence Compendium 2002 Theoretical Biology Biophysics Group, Los Alamos National Laboratory Los Alamos, NM LA-UR 03-3564
15. K. Liitsola, T. Laukkanen, A. Denisova, A. Grishkevichius, T. Smolskaja, V. Ustina, N. Vlasov, P. Leinikki, and M.O. Salminen Genetic characterization of HIV-1 strains in the Baltic countries and Russia Scand. J. Infect. Dis. 28 1996 537 541
16. K. Liitsola, I. Tashkinova, T. Laukkanen, G. Korovina, T. Smolskaja, O. Momot, N. Mashkilleyson, S. Chaplinskas, H. Brummer-Korvenkontio, J. Vanhatalo, P. Leinikki, and M.O. Salminen HIV-1 genetic subtype A/B recombinant strain causing an explosive epidemic in injecting drug users in Kaliningrad AIDS 12 1998 1907 1919
17. S.J. Little, E.S. Daar, R.T. D'Aquila, P.H. Keiser, E. Connick, J.M. Whitcomb, N.S. Hellmann, C.J. Petropoulos, L. Sutton, J.A. Pitt, E.S. Rosenberg, R.A. Koup, B.D. Walker, and D.D. Richman Reduced antiretroviral drug susceptibility among patients with primary HIV infection JAMA 282 1999 1142 1149
18. S.J. Little, S. Holte, J.P. Routy, E.S. Daar, M. Markowitz, A.C. Collier, R.A. Koup, J.W. Mellors, E. Connick, B. Conway, M. Kilby, L. Wang, J.M. Whitcomb, N.S. Hellmann, and D.D. Richman Antiretroviral-drug resistance among patients recently infected with HIV N. Engl. J. Med. 347 2002 385 394
19. P. Lorenzi, M. Opravil, B. Hirschel, J.P. Chave, H.J. Furrer, H. Sax, T.V. Perneger, L. Perrin, L. Kaiser, S. Yerly Swiss HIV Cohort Study Impact of drug resistance mutations on virologic response to salvage therapy AIDS 13 1999 17 21
20. E. Magiorkinis, D. Paraskevis, G. Magiorkinis, S. Chryssou, M. Chini, M. Lazanas, V. Paparizos, G. Saroglou, A. Antoniadou, E. Giamarellou, A. Karafoulidou, and A. Hatzakis Mutations associated with genotypic resistance to antiretroviral therapy in treatment naive HIV-1 infected patients in Greece Virus Res. 85 2002 109 115
21. C.F. Perno, A. Cozzi-Lepri, C. Balotta, A. Bertoli, M. Violin, L. Monno, T. Zauli, M. Montroni, G. Ippolito, A. d'Arminio-Monforte I.CO.N.A Study Group Low prevalence of primary mutations associated with drug resistance in antiviral-naive patients at therapy initiation AIDS 16 2002 619 624
22. C.F. Perno, A. Cozzi-Lepri, C. Balotta, F. Forbici, M. Violin, A. Bertoli, G. Facchi, P. Pezzotti, G. Cadeo, G. Tositti, S. Pasquinucci, S. Pauluzzi, A. Scalzini, B. Salassa, A. Vincenti, A.N. Phillips, F. Dianzani, A. Appice, G. Angarano, L. Monno, G. Ippolito, M. Moroni, A. d'Arminio-Monforte Italian Cohort Naive Antiretroviral (I.CO.N.A.) Study Group Secondary mutations in the protease region of human immunodeficiency virus and virological failure in drug-naive patients treated with protease inhibitor-based therapy J. Infect. Dis. 184 2001 983 991
23. L. Romano, G. Venturi, S. Bloor, R. Harrigan, B.A. Larder, J.C. Major, and M. Zazzi Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118 J. Infect. Dis. 185 2002 898 904
24. H.A. Schmidt, K. Strimmer, M. Vingron, and A. von Haeseler TREE-PUZZLE: maximum likelihood phylogenetic analysis using quartets and parallel computing Bioinformatics 18 2002 502 504
25. Schmit, J.C., Lambert, C., Fontaine, E., Fischer, A., Weber, G., Staub, T., Schneider, V., Arendt, V., Hemmer, R., November 2002. High Incidence of Genetic Drug Resistance Markers in Newly Diagnosed Patients in the Luxembourg HIV Cohort. Sixth International Congress on Drug Therapy in HIV Infection. Glasgow, UK (Abstract P225).
26. T. Shirasaka, M.F. Kavlick, T. Ueno, W.Y. Gao, E. Kojima, M.L. Alcaide, S. Chokekijchai, B.M. Roy, E. Arnold, and R. Yarchoan Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides Proc. Natl. Acad. Sci. U.S.A. 92 1995 2398 2402
27. Stanojevic, M., Jevtovic, D., Salemovic, D., Van Laethem, K., Schrooten, Y., Jovanic, T., Vandamme, A.M., March 2004. Prevalence of Mutations Associated with Antiretroviral Drug Resistance among Newly Diagnosed Patients in Serbia and Montenegro. Second European HIV Drug Resistance Workshop: from Basic Science to Clinical Implications. Rome, Italy (Abstract 12).
28. The EACS Euroguidelines Group European guidelines for the clinical management and treatment of HIV-infected adults in Europe AIDS 17 2003 S3 S27
29. J.D. Thompson, D.G. Higgins, and T.J. Gibson CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice Nucleic Acids Res. 22 1994 4673 4680
30. D. Turner, B. Brenner, D. Moisi, M. Detorio, R. Cesaire, T. Kurimura, H. Mori, M. Essex, S. Maayan, and M.A. Wainberg Nucleotide and amino acid polymorphisms at drug resistance sites in non-B-subtype variants of human immunodeficiency virus type 1 Antimicrob. Agents Chemother. 48 2004 2993 2998
31. van de Vijver, D.A.M.C., Wensing, A.M.J., Op de Coul, E., Angarano, G., Åsjö, B., Balotta, C., Boeri, E., Camacho, R., Chaix, M.-L., Costagliola, D., de Luca, A., Maljkovic, I., de Mendoza, C., Derdelinckx, I., Grossman, Z., Hamouda, O., Hatzakis, A., Hoepelman, I.M., Hemmer, R., Horban, A., Korn, K., Kücherer, C., Leitner, T., Loveday, C., MacRae, E., Nielsen, C., Ormaasen, V., Perrin, L., Paraskevis, D., Puchhammer-Stöckl, E., Ruiz, L., Salminen, M., Schmit J.C.C., Schneider. F., Schuurman, R., Soriano, V., Stanczak, G., Stanojevic, M., Vandamme, A.-M., Van Laethem, K., Violin, M., Wilbe, K., Yerly, S., Zazzi, M., Boucher, C.A.B. on behalf of the SPREAD Programme., March 2004. Increasing Prevalence of HIV-1 Non-B Subtypes across Europe from 1996-1999 to 2000-2002; Results from the CATCH-Study. Oral Presentation at the 2nd European HIV drug Resistance Workshop. Rome, Italy.
32. K. Van Vaerenbergh, L. Debaisieux, N. De Cabooter, C. Declercq, K. Desmet, K. Fransen, B. Maes, D. Marissens, K. Miller, G. Muyldermans, S. Sprecher, L. Stuyver, D. Vaira, C. Verhofstede, G. Zissis, M. Van Ranst, E. De Clercq, J. Desmyter, and A.-M. Vandamme Prevalence of genotypic resistance among Belgian antiretroviral drug-naive HIV-1 infected patients and its consequences for therapy response Antivir. Ther. 6 2001 63 70
33. A.M. Vandamme, A. Sonnerborg, M. Ait-Khaled, J. Albert, B. Asjo, L. Bacheler, D. Banhegyi, C. Boucher, F. Brun-Vezinet, R. Camacho, P. Clevenbergh, N. Clumeck, N. Dedes, A. De Luca, H.W. Doerr, J.L. Faudon, G. Gatti, J. Gerstoft, W.W. Hall, A. Hatzakis, N. Hellmann, A. Horban, J.D. Lundgren, D. Kempf, M. Miller, V. Miller, T.W. Myers, C. Nielsen, M. Opravil, L. Palmisano, C.F. Perno, A. Phillips, D. Pillay, T. Pumarola, L. Ruiz, M. Salminen, J. Schapiro, B. Schmidt, J.C. Schmit, R. Schuurman, E. Shulse, V. Soriano, S. Staszewski, S. Vella, M. Youle, R. Ziermann, and L. Perrin Updated European recommendations for the clinical use of HIV drug resistance testing Antivir. Ther. 9 2004 829 848
34. M. Violin, R. Velleca, and A. Cozzi-Lepri Prevalence of HIV-1 primary drug resistance in seroconverters of the ICoNA cohort over the period 1996-2001 J. Acquir. Immune Defic. Syndr. 36 2004 761 764
35. H.S. Weinstock, I. Zaidi, W. Heneine, D. Bennett, J.G. Garcia-Lerma, J.M. Douglas Jr., M. LaLota, G. Dickinson, S. Schwarcz, L. Torian, D. Wendell, S. Paul, G.A. Goza, J. Ruiz, B. Boyett, and J.E. Kaplan The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities J. Infect. Dis. 189 2004 2174 2180
36. A.M. Wensing, and C.A. Boucher Worldwide transmission of drug-resistant HIV AIDS Rev. 5 2003 140 155
37. A.M.J. Wensing, D.A.M.C. van de Vijver, B. Åsjø, C. Balotta, R. Camacho, A. De Luca, C. de Mendoza, I. Derdelinckx, Z. Grossman, O. Hamouda, A. Hatzakis, R. Hemmer, A. Hoepelman, A. Horban, K. Korn, C. Kücherer, T. Leitner, C. Loveday, E. Macrae, I. Maljkovic, C. Nielsen, V. Ormaasen, L. Perrin, D. Paraskevis, E. Puchhammer, L. Ruiz, M. Salminen, J. Schmit, F. Schneider, R. Schurrmann, V. Soriano, G. Stanczak, M. Stanojevic, A. Vandamme, K. Van Laethem, M. Violin, K. Wilbe, S. Yerly, M. Zazzi, and C. Boucher Analysis from more than 1600 Newly Diagnosed Patients with HIV from 17 European Countries shows that 10% of the Patients Carry Primary Drug Resistance: The CATCH-Study (Abstract LB01) 2003 Second International AIDS Society Conference Paris
38. P.G. Yeni, S.M. Hammer, M.S. Hirsch, M.S. Saag, M. Schechter, C.C. Carpenter, M.A. Fischl, J.M. Gatell, B.G. Gazzard, D.M. Jacobsen, D.A. Katzenstein, J.S. Montaner, D.D. Richman, R.T. Schooley, M.A. Thompson, S. Vella, and P.A. Volberding Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel JAMA 292 2004 251 265
39. S. Yerly, L. Kaiser, E. Race, J.P. Bru, F. Clavel, and L. Perrin Transmission of antiretroviral-drug-resistant HIV-1 variants Lancet 354 1999 729 733